Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,349 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,726 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05968170 | TCRαβ/CD19 Depletion of Stem Cell Grafts for Transplant | withdrawn | N/A | 0 | Neena Kapoor, M.D.OTHER | 0 | Jul 14, 2025 | clinicaltrials |
| NCT06086925 | A Window of Opportunity Study of Black Raspberry for Patients With HNSCC | withdrawn | Early Phase 1 | 0 | Mitchell MachtayOTHER | 0 | Jul 11, 2025 | clinicaltrials |
| NCT05879484 |
| Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS |
| withdrawn |
| Phase 1 / Phase 2 |
| 0 |
| National Cancer Institute (NCI)NIH |
| 1 |
| Jul 10, 2025 |
| clinicaltrials |
| NCT05257707 | Molecular Markers in Cancers and Precancers (MOCA)(MOCA) | withdrawn | N/A | 0 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Jul 9, 2025 | clinicaltrials |
| NCT06508827 | Intravenous Iron in Combination With Standard of Care Immunotherapy in Melanoma | withdrawn | Phase 2 | 0 | Indiana UniversityOTHER | 0 | Jul 9, 2025 | clinicaltrials |
| NCT04838782 | Role of Repeat Resection in Recurrent Glioblastoma | withdrawn | N/A | 0 | University of AlbertaOTHER | 1 | Jul 8, 2025 | clinicaltrials |
| NCT05222308 | Advanced Planning for Online Accounts and Data | withdrawn | N/A | 0 | University of Colorado, DenverOTHER | 0 | Jul 8, 2025 | clinicaltrials |
| NCT04569461 | Trimodality Approach of Low Dose iOnizing Radiation With or Without Neoadjuvant Pembrolizumab and Prostatectomy for Men With Intermediate/High Risk Prostate Cancer (TALON)(TALON) | withdrawn | Phase 2 | 0 | Duke UniversityOTHER | 1 | Jul 4, 2025 | clinicaltrials |
| NCT06013904 | Difficult PIV Placement in the Pediatric ED | withdrawn | N/A | 0 | University of Texas at AustinOTHER | 0 | Jul 4, 2025 | clinicaltrials |
| NCT06590558 | Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Jul 3, 2025 | clinicaltrials |
| NCT07046481 | Physical Activity and Quality of Life in Childhood Cancersurvivors- a Long-term Follow-up | withdrawn | N/A | 0 | Region SkaneOTHER | 0 | Jul 1, 2025 | clinicaltrials |
| NCT06416436 | Dose-escalation Study of Ultra-high Dose Ablative Radiosurgery With Immunotherapy for Bulky Metastatic Cancer Patients | withdrawn | Phase 1 | 0 | University of Kansas Medical CenterOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT06572189 | The Safety and Efficacy of CD-801 in Patients With Advanced Intrahepatic Cholangiocarcinoma | withdrawn | Early Phase 1 | 0 | Shanghai Changzheng HospitalOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT05538988 | BIOmarker-guided Study to Evaluate the Efficacy and Safety of cemipLimab for advancEd Cutaneous T-cell Lymphoma(BIOSELECT) | withdrawn | Phase 1 / Phase 2 | 0 | AHS Cancer Control AlbertaOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT04688333 | iConquerFear Program for the Treatment of Fear of Cancer Recurrence in Patients With Localized Renal Cell Carcinoma | withdrawn | — | 0 | City of Hope Medical CenterOTHER | 0 | Jun 26, 2025 | clinicaltrials |
| NCT06852560 | A Trial Assessing Feasibility of Allostatic Load Biomarkers and CVD Risk Among Black Breast Cancer Survivors(GEM) | withdrawn | N/A | 0 | University of FloridaOTHER | 0 | Jun 26, 2025 | clinicaltrials |
| NCT03941223 | Regional Anesthesia for Breast Surgery | withdrawn | N/A | 0 | Azienda USL Reggio Emilia - IRCCSOTHER_GOV | 1 | Jun 25, 2025 | clinicaltrials |
| NCT05333432 | Evaluation of a Multimodal Strategy for Early Diagnosis of Men at High Genetic Risk of Prostate Cancer(HRPCa-II) | withdrawn | N/A | 0 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Jun 25, 2025 | clinicaltrials |
| NCT06707896 | TCR1020-CD8 T Cells in KRAS-mutated Cancers | withdrawn | Phase 1 | 0 | University of PennsylvaniaOTHER | 0 | Jun 25, 2025 | clinicaltrials |
| NCT05521087 | A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias | withdrawn | Phase 1 | 0 | Janssen Research & Development, LLCINDUSTRY | 0 | Jun 22, 2025 | clinicaltrials |
| NCT06719973 | Phase 1 Study of M9466 Combined With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521) | withdrawn | Phase 1 | 0 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 0 | Jun 17, 2025 | clinicaltrials |
| NCT05687721 | Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer | withdrawn | Phase 1 / Phase 2 | 0 | VA Office of Research and DevelopmentFED | 1 | Jun 15, 2025 | clinicaltrials |
| NCT05106192 | Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System. | withdrawn | N/A | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT05248685 | Optimized Dual CD33/CLL1 CAR T Cells in Subjects With Refractory or Relapsed Acute Myeloid Leukemia | withdrawn | Phase 1 | 0 | Beijing Boren HospitalOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT05067842 | Circulating Tumor DNA (ctDNA) in Locally Advanced Esophageal and Gastroesophageal (GE) Junction Adenocarcinoma(TRACT DNA) | withdrawn | — | 0 | Medical College of WisconsinOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT04142398 | Incidence of HPV Infection and HPV-Associated Disease in Screening Indian Men Who Have Sex With HIV-Positive Men | withdrawn | — | 0 | AIDS Malignancy ConsortiumNETWORK | 2 | Jun 6, 2025 | clinicaltrials |
| NCT06592664 | Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC(FORTIFIDE) | withdrawn | Phase 1 / Phase 2 | 0 | Lisata Therapeutics, Inc.INDUSTRY | 0 | Jun 6, 2025 | clinicaltrials |
| NCT04099446 | A Non-Interventional Pilot Study to Explore the Skin Microbes in Skin Cancer | withdrawn | — | 0 | ProgenaBiomeOTHER | 1 | Jun 5, 2025 | clinicaltrials |
| NCT04148378 | A Pilot Study to Explore the Role of Gut Flora in Colorectal Cancer | withdrawn | — | 0 | ProgenaBiomeOTHER | 1 | Jun 5, 2025 | clinicaltrials |
| NCT04214015 | A Pilot Study to Explore the Role of Gut Flora in Metastatic Mesothelioma | withdrawn | — | 0 | ProgenaBiomeOTHER | 1 | Jun 5, 2025 | clinicaltrials |
| NCT06190249 | Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma | withdrawn | Phase 1 | 0 | James Isaacs, MDOTHER | 0 | Jun 5, 2025 | clinicaltrials |
| NCT02077621 | Study of PG2 Injection for Improving Fatigue in Patients After Palliative Abdominal Surgery for Cancer | withdrawn | Phase 2 | 0 | PhytoHealth CorporationINDUSTRY | 1 | Jun 4, 2025 | clinicaltrials |
| NCT06494046 | Defining Musical Toxicity and Its Effect on Patient Well-being | withdrawn | — | 0 | Mayo ClinicOTHER | 1 | Jun 4, 2025 | clinicaltrials |
| NCT06393751 | Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Jun 3, 2025 | clinicaltrials |
| NCT06770257 | Daunorubicin, Cytarabine Liposomes Plus Venetoclax vs Azacitidine Plus Venetoclax in AML Patients Unfit for Intensive Chemotherapy | withdrawn | Phase 2 | 0 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Jun 3, 2025 | clinicaltrials |
| NCT00535314 | Study of Two Dose Levels of RTA 402 in Patients With Advanced Malignant Melanoma | withdrawn | Phase 2 | 0 | BiogenINDUSTRY | 0 | May 31, 2025 | clinicaltrials |
| NCT02446652 | Evaluation of TRANSKRIP ® Plus Chemotherapy in Recurrent-Persistent Cervical Cancer | withdrawn | Phase 3 | 0 | National Institute of CancerologíaOTHER_GOV | 1 | May 29, 2025 | clinicaltrials |
| NCT05840770 | Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | City of Hope Medical CenterOTHER | 0 | May 26, 2025 | clinicaltrials |
| NCT05287347 | Panc CA Risk Model & Biomarker Testing In High-Risk Cohort | withdrawn | — | 0 | Beth Israel Deaconess Medical CenterOTHER | 1 | May 25, 2025 | clinicaltrials |
| NCT04820894 | Perception of Cure Among Patients With Metastatic Cancer | withdrawn | — | 0 | City of Hope Medical CenterOTHER | 0 | May 23, 2025 | clinicaltrials |
| NCT05672095 | Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer | withdrawn | Phase 1 / Phase 2 | 0 | City of Hope Medical CenterOTHER | 0 | May 23, 2025 | clinicaltrials |
| NCT06361758 | Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC | withdrawn | Phase 2 | 0 | Shanghai Zhongshan HospitalOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT04685915 | Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL | withdrawn | Phase 2 | 0 | Inhye AhnOTHER | 0 | May 22, 2025 | clinicaltrials |
| NCT05927610 | Genetic Testing of Cerebrospinal Fluid to Diagnose and Monitor Glioblastoma | withdrawn | N/A | 0 | Memorial Sloan Kettering Cancer CenterOTHER | 0 | May 21, 2025 | clinicaltrials |
| NCT05990478 | A Study of Contrast-Enhanced Mammography (CEM) Scans in People With Breast Cancer | withdrawn | — | 0 | Memorial Sloan Kettering Cancer CenterOTHER | 0 | May 21, 2025 | clinicaltrials |
| NCT06895577 | Neoadjuvant Chemoradiotherapy Plus Sintilimab for MSS, Locally Advanced Rectal Cancer- | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | May 21, 2025 | clinicaltrials |
| NCT01125449 | Study of High Dose Intravenous (IV) Ascorbic Acid in Measurable Solid Tumor Disease | withdrawn | Phase 2 | 0 | Situs Cancer Research CenterOTHER | 1 | May 18, 2025 | clinicaltrials |
| NCT06145399 | A Study of 1 8F-FDHT PET/MRIScans in Women With Breast Cancer | withdrawn | Early Phase 1 | 0 | Memorial Sloan Kettering Cancer CenterOTHER | 0 | May 18, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jul 14, 2025source: clinicaltrials